PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
43.14%
Similar G&A growth to TRVN's 54.80%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.75%
Operating expenses reduction while TRVN shows 7.09% growth. Joel Greenblatt would examine advantage.
-7.75%
Total costs reduction while TRVN shows 7.09% growth. Joel Greenblatt would examine advantage.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
975.86%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
-265.35%
EBITDA decline while TRVN shows 4.32% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
7.75%
Operating income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-2437.42%
Other expenses reduction while TRVN shows 258.45% growth. Joel Greenblatt would examine advantage.
-313.81%
Pre-tax income decline while TRVN shows 21.37% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-313.81%
Net income decline while TRVN shows 21.37% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-286.19%
EPS decline while TRVN shows 32.48% growth. Joel Greenblatt would examine position.
-286.19%
Diluted EPS decline while TRVN shows 32.48% growth. Joel Greenblatt would examine position.
6.89%
Share count reduction exceeding 1.5x TRVN's 16.44%. David Dodd would verify capital allocation.
6.89%
Diluted share reduction exceeding 1.5x TRVN's 16.44%. David Dodd would verify capital allocation.